Abstract
Background. Maintenance hemodialysis (MHD) patients with polycystic kidney disease (PKD) have better survival than non-PKD patients. Mineral and bone disorders (MBD) are associated with accelerated atherosclerosis and cardiovascular death in MHD patients. It is unknown whether the different MBD mortality association between MHD populations with and without PKD can explain the survival differential.

Methods. Survival models were examined to assess the association between different laboratory markers of MBD [such as serum phosphorus, parathyroid hormone (PTH), calcium and alkaline phosphatase] and mortality in a 6-year cohort of 60,089 non-PKD and 1,501 PKD MHD patients.

Results. PKD and non-PKD patients were 57 ± 13 and 62 ± 15 years old and included 46 and 45% women and 14 and 32% Blacks, respectively. Whereas PKD individuals with PTH 150 to <300 pg/mL (reference) had the lowest risk for mortality, the death risk was higher in patients with PTH <150 [hazard ratio (HR): 2.16 (95% confidence interval 1.53–3.06)], 300 to <600 [HR: 1.30 (0.97–1.74)] and ≥600 pg/mL [HR: 1.46 (1.02–2.08)], respectively. Similar patterns were found in non-PKD patients. Fully adjusted death HRs of time-averaged serum phosphorus increments <3.5, 3.5 to <7.5 and ≥7.5 mg/dL (reference: 3.5 to <5.5 mg/dL) for PKD patients were 2.82 (1.50–5.29), 1.40 (1.12–1.75) and 2.25 (1.57–3.22). The associations of alkaline phosphatase and calcium with mortality were similar in PKD and non-PKD patients.

Conclusion. Bone–mineral disorder markers exhibit similar mortality trends between PKD and non-PKD MHD patients, although some differences are observed in particular in low PTH and phosphorus ranges.

Keywords: hemodialysis; mineral and bone disorders; mortality; parathyroid hormone; polycystic kidney disease

Introduction
Although maintenance dialysis prevents death from uremia, patient survival remains an important issue. Once renal replacement therapy is initiated, the range of the expected remaining life span in the United States Renal Data System (USRDS) report was ~8 years (varies with race) for dialysis patients aged 40–44 years and ~4.5 years for those aged 60–64 years [1]. Cardiovascular disease accounts for ~50% of deaths. While a decline in cardiovascular deaths has occurred in the general population, a similar trend has not been observed in dialysis patients [1]. Accelerated atherosclerosis is an important cause of cardiovascular death in long-term dialysis patients [2] and shows strong association with mineral and bone disorders (MBD) in these patients [3]. Serum phosphorous, calcium and parathyroid hormone (PTH) levels help us to assess MBD in these patients; however, a recent meta-analysis in chronic kidney disease (CKD) patients suggested that only serum phosphorous level was a strong and independent predictor of mortality [4].

Approximately 5% of end-stage renal disease (ESRD) patients in the USA suffer from polycystic kidney disease (PKD) [5]. There is a relative paucity of data for ESRD patients with PKD [6–8]. Those PKD patients who require maintenance hemodialysis (MHD) treatment seem to be different from other MHD patients: they report a better quality of life [9] and have greater survival than non-PKD patients, including non-diabetic MHD patients.
The relative risk of death is substantially lower among MHD patients with PKD compared to non-diabetic dialysis patients [10, 12], a survival advantage that is also observed among peritoneal dialysis patients with PKD [15]. Orskov et al. [16] demonstrated that in Danish patients with PKD, the prognosis had significantly improved during the last decade. There are certain factors that may potentially affect the association between MBD markers and mortality in ESRD patients with PKD. Fibroblast growth factor 23 level was substantially elevated in PKD patients compared with glomerular filtration rate-matched CKD patients and was associated with an apparent renal phosphate leak, while PTH and vitamin D metabolite levels remained in the normal range [17]. However, this difference might not be true in patients on maintenance dialysis. These differences raise questions as to whether the MBD mortality association is different in PKD patients and in the general MHD population and if the survival difference between PKD and general MHD patients is due to the consequence of different MBD mortality association between these groups.

Given the greater survival and lower comorbidity burden in PKD patients compared to other MHD patients, we hypothesized that associations of PTH, calcium and phosphorus with mortality are different in MHD patients with PKD and without PKD.

Materials and methods

Patients

We extracted, refined and examined data from all individuals with ESRD who underwent dialysis treatment from July 2001 through June 2006 in any one of the 580 outpatient dialysis facilities of DaVita, a large dialysis organization in the USA (prior to its acquisition of units owned by Gambro). Of the 164,789 cumulative patients treated in all DaVita units over the 5-year period, we excluded 13,312 patients without quarterly baseline data, 19,652 patients who were on peritoneal dialysis or in whom the method of renal replacement therapy was unknown and 802 patients aged <99 years or <18 years. From these 131,023 patients, 60,089 did not have PTH data; therefore, our study population of PTH analysis consisted of 1501 MHD patients with PKD and 69,433 MHD patients without PKD. In our calcium, phosphorus and alkaline phosphatase analysis, we included 119,128, 111,587 and 115,432 patients, respectively, who had calcium, phosphorus and alkaline phosphatase time-averaged data. The study was approved by relevant Institutional Review Committees.

Clinical and demographic measures

The creation of the cohort has been described previously [18–25]. To minimize measurement variability, all repeated measures for each patient during any given calendar quarter, i.e. over a 13-week interval, were averaged and the summary estimate was used in all models. Average PTH, calcium, phosphorus and alkaline phosphatase values were obtained from up to 20 calendar quarters (q1 through q20). The first (baseline) study quarter for each patient was the calendar quarter in which the patient’s dialysis vintage was >90 days. The presence or absence of diabetes at baseline and history of tobacco smoking were obtained by linking the DaVita database to the data from Medical Evidence Form 2728 from the USRDS. The presence of preexisting comorbidity conditions was similarly ascertained and grouped into nine categories: ischemic heart disease, congestive heart failure, history of hypertension, history of other cardiac disease, cerebrovascular events, peripheral vascular disease, chronic obstructive pulmonary disease, ability to ambulate and cancer [26]. We did not use HIV/AIDS status in this analysis due to large amount of missing data on these conditions as well as due to the fact that many available data had HIV/AIDS status listed as ‘undisclosed’. Patients were followed for outcomes through 30 June 2007.

Laboratory measures

Blood samples were drawn using uniform techniques in all dialysis clinics and were transported to the DaVita Laboratory in Deland, Florida within 24 h. All laboratory values, including PTH, calcium, phosphorus and alkaline phosphatase, were measured by automated and standardized methods. The 3-month-averaged PTH, calcium, phosphorus and alkaline phosphatase for each quarter were used in our analyses. We divided PTH a priori into four categories (<150, 150 to <300, 300 to <600 and ≥600 pg/mL). We have used the following equation to calculate the corrected calcium level ‘corrected calcium = [0.8 × [normal albumin (4 g/dL) – patients’ albumin]] + serum calcium’. We divided corrected calcium level a priori into four categories (<8.4, 8.4 to <9.5, 9.5 to <10.2 and ≥10.2 mg/dL), phosphorus level a priori into four categories (<3.5, 3.5 to <5.5, 5.5 to <7.5 and ≥7.5 mg/dL) and alkaline phosphatase level a priori into four categories (<80, 80 to <120, 120 to <160 and ≥160 U/L).

Epidemiologic and statistical methods

Data were summarized using proportions and means (±SD). The significance of the difference between categorical variables was determined using the chi-square test and between continuous variables using analysis of variance, as appropriate. Survival analysis was performed by fitting time-averaged Cox proportional hazard models to examine whether PTH, corrected calcium, phosphorus and alkaline phosphatase predicted survival in PKD and non-PKD patients. The presence of non-linearity in the survival associations was tested by adding the quadratic term of markers of MBD to the models already containing the linear term. For each analysis, including subgroup analyses, three models were examined:

(1) Unadjusted or minimally adjusted models included PTH, corrected calcium, phosphorus and alkaline phosphatase categories and entry calendar quarter (q1 through q20).

(2) Case-mix adjusted models that included all variables included in minimally adjusted model plus age, gender, presence of diabetes, race/ethnicity (African-Americans and other self-categorized Blacks, non-Hispanic Caucasians, Asians, Hispanics and others), categories of dialysis vintage (<6 months, 6–12 months, 12–24 months and ≥22 years), primary insurance (Medicare, Medicaid and others) and marital status (married, single, divorced or widowed), type of vascular access (catheter, arteriovenous fistula or graft), dialysis dose as indicated by Kt/V (single pool), nine preexisting comorbidity conditions and history of tobacco smoking.

(3) Case-mix plus malnutrition–inflammation complex syndrome (MICS) adjusted models included all the covariates in the case-mix model as well as body mass index (BMI) and nine laboratory surrogates with known association with clinical outcomes in hemodialysis (HD) patients including serum levels of albumin, total iron binding capacity (TIBC), creatinine, calcium (except model where calcium was predictor, phosphorus where phosphorus was predictor), bicarbonate, normalized protein catabolic rate as an indicator of daily protein intake, also known as the normalized protein nitrogen appearance, white blood cell count (WBC) and lymphocyte percentage.

For all analysis, two-sided P-values are reported and results were considered statistically significant if P < 0.05. All statistical analyses were carried out with the SAS, version 9.1 (SAS Institute Inc., Cary, NC).

Results

The baseline demographic, clinical and laboratory characteristics of the 1501 PKD and 69,433 non-PKD patients, divided into four subgroups based on PTH categories, are summarized in Table 1. PKD and non-PKD patients were 57 ± 13 and 62 ± 15 years old and included 46 and 45% women and 14 and 32% Blacks, respectively. In the PKD and non-PKD populations, higher PTH level was associated with younger age, higher proportion of Blacks and higher serum phosphorous and
Table 1. Baseline characteristics of patients across baseline intact parathyroid hormone categories in 70,934 MHD patients, including 1501 MHD patients with PKD and 69,433 MHD patients with non-PKD

<table>
<thead>
<tr>
<th></th>
<th>PKD Non-PKD</th>
<th>PKD Non-PKD</th>
<th>PKD Non-PKD</th>
<th>PKD Non-PKD</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>PTH &lt;150 (pg/mL); n = 357</td>
<td>PTH 150 to &lt;300 (pg/mL); n = 468</td>
<td>PTH 300 to &lt;600 (pg/mL); n = 407</td>
<td>PTH ≥600 (pg/mL); n = 269</td>
</tr>
<tr>
<td></td>
<td>P*</td>
<td>PTH &lt;150 (pg/mL); n = 20,503</td>
<td>PTH 150 to &lt;300 (pg/mL); n = 23,171</td>
<td>PTH 300 to &lt;600 (pg/mL); n = 16,950</td>
</tr>
<tr>
<td>Age (years)</td>
<td>60 ± 13</td>
<td>59 ± 13</td>
<td>57 ± 13</td>
<td>53 ± 13</td>
</tr>
<tr>
<td>Gender (% female)</td>
<td>49</td>
<td>46</td>
<td>50</td>
<td>42</td>
</tr>
<tr>
<td>Diabetes mellitus (%)</td>
<td>13</td>
<td>16</td>
<td>13</td>
<td>14</td>
</tr>
<tr>
<td>Race (%)</td>
<td>White</td>
<td>70</td>
<td>68</td>
<td>61</td>
</tr>
<tr>
<td></td>
<td>Black</td>
<td>11</td>
<td>13</td>
<td>19</td>
</tr>
<tr>
<td></td>
<td>Hispanic</td>
<td>9</td>
<td>9</td>
<td>13</td>
</tr>
<tr>
<td></td>
<td>Asian</td>
<td>2</td>
<td>3</td>
<td>1</td>
</tr>
<tr>
<td></td>
<td>Other</td>
<td>8</td>
<td>7</td>
<td>6</td>
</tr>
<tr>
<td>Vintage [time on dialysis (%)]</td>
<td>0–6 Months</td>
<td>9</td>
<td>14</td>
<td>16</td>
</tr>
<tr>
<td></td>
<td>6–24 Months</td>
<td>20</td>
<td>17</td>
<td>15</td>
</tr>
<tr>
<td></td>
<td>2–5 Years</td>
<td>40</td>
<td>45</td>
<td>42</td>
</tr>
<tr>
<td></td>
<td>&gt;5 Years</td>
<td>31</td>
<td>24</td>
<td>27</td>
</tr>
<tr>
<td>Primary insurance (%)</td>
<td>Medicare</td>
<td>59</td>
<td>53</td>
<td>58</td>
</tr>
<tr>
<td></td>
<td>Medicaid</td>
<td>4</td>
<td>5</td>
<td>3</td>
</tr>
<tr>
<td></td>
<td>Other</td>
<td>9</td>
<td>18</td>
<td>14</td>
</tr>
<tr>
<td>Marital status (%)</td>
<td>Married</td>
<td>60</td>
<td>62</td>
<td>59</td>
</tr>
<tr>
<td></td>
<td>Divorced</td>
<td>8</td>
<td>7</td>
<td>12</td>
</tr>
<tr>
<td></td>
<td>Single</td>
<td>19</td>
<td>21</td>
<td>20</td>
</tr>
<tr>
<td></td>
<td>Widowed</td>
<td>13</td>
<td>9</td>
<td>9</td>
</tr>
<tr>
<td>Other variables (mean ± SD)</td>
<td>Kt/V (dialysis dose)</td>
<td>1.60 ± 0.32</td>
<td>1.59 ± 0.37</td>
<td>1.52 ± 0.34</td>
</tr>
<tr>
<td></td>
<td>BMI (kg/m²)</td>
<td>25.5 ± 5.3</td>
<td>26.0 ± 6.2</td>
<td>26.8 ± 6.0</td>
</tr>
<tr>
<td>Vascular access (%)</td>
<td>Catheter</td>
<td>27</td>
<td>26</td>
<td>31</td>
</tr>
<tr>
<td></td>
<td>AVF</td>
<td>39</td>
<td>43</td>
<td>37</td>
</tr>
<tr>
<td></td>
<td>Graft</td>
<td>34</td>
<td>31</td>
<td>32</td>
</tr>
<tr>
<td>Comorbid conditions (%)</td>
<td>Cancer</td>
<td>2.8</td>
<td>3.2</td>
<td>2.7</td>
</tr>
<tr>
<td></td>
<td>Atherosclerotic heart disease</td>
<td>11.8</td>
<td>11.3</td>
<td>10.6</td>
</tr>
<tr>
<td></td>
<td>Heart failure</td>
<td>10.9</td>
<td>9.8</td>
<td>8.4</td>
</tr>
<tr>
<td></td>
<td>Chronic obstructive pulmonary disease</td>
<td>5.9</td>
<td>4.3</td>
<td>3.0</td>
</tr>
<tr>
<td></td>
<td>Cerebrovascular disease</td>
<td>5.0</td>
<td>5.6</td>
<td>3.2</td>
</tr>
<tr>
<td></td>
<td>History of hypertension</td>
<td>77.6</td>
<td>78.2</td>
<td>76.9</td>
</tr>
<tr>
<td></td>
<td>Other heart diseases</td>
<td>5.3</td>
<td>3.9</td>
<td>4.7</td>
</tr>
<tr>
<td></td>
<td>Non-ambulatory</td>
<td>0</td>
<td>1.5</td>
<td>0.3</td>
</tr>
<tr>
<td></td>
<td>Peripheral vascular disease</td>
<td>5.3</td>
<td>2.8</td>
<td>3.0</td>
</tr>
<tr>
<td></td>
<td>Smoker</td>
<td>4.8</td>
<td>4.3</td>
<td>5.4</td>
</tr>
</tbody>
</table>

Serum levels (at baseline) (continued)
creatinine levels (Table 1). Additionally, in the non-PKD population, it was associated with higher BMI and serum calcium level (Table 1). In contrast, in the PKD population, it was associated with a lower serum calcium level (Table 1). The median follow-up time for the cohort was 686 days (interquartile range: 332–1195 days).

Figure 1A shows unadjusted, case-mix and MICS adjusted death hazard ratios (HRs) for time-averaged PTH levels in PKD patients. The association was U-shaped in both subgroups. While PKD individuals with PTH 150–300 pg/mL (as reference) had the lowest risk for mortality, the death risk was higher in patients with PTH <150 [HR: 2.16, 95% confidence interval (CI) 1.53–3.06], 300–600 (HR: 1.30; 95% CI 0.97–1.74) and ≥600 (HR: 1.46; 95% CI 1.02–2.08) pg/mL, respectively, in our fully adjusted model (P > 0.05 for the quadratic PTH term in case-mix and P > 0.05 in MICS models) (Figure 1A). A similar pattern was found in non-PKD patients. The association between PTH and mortality was not modified by the presence of PKD (P > 0.05 for interaction term). Figure 1B shows pooled analyses comparing mortality predictability of PTH increments in PKD versus non-PKD patients (PTH reference: 150 to <300 pg/mL in non-PKD patients). PKD patients have lower mortality risk than non-PKD patients in higher PTH categories (>150 pg/mL).

Figure 2A shows unadjusted, case-mix and MICS adjusted death HR for time-averaged corrected calcium levels in PKD patients. Fully adjusted death HRs (95% CI) associated with time-averaged corrected calcium levels of <8.4, 9.5 to <10.2 and ≥10.2 mg/dL (reference: 8.4 to <9.5 mg/dL) for PKD patients were 0.75 (0.43–1.29), 0.83 (0.69–1.00) and 1.19 (0.94–1.50) (P = 0.02 for the quadratic corrected calcium term in case-mix and MICS models), respectively, and similar pattern was found in non-PKD patients. The association between corrected calcium and mortality was not modified by presence of PKD (P > 0.05 for interaction term). Figure 2B shows pooled analyses comparing mortality predictability of corrected calcium increments in PKD versus non-PKD patients (corrected calcium reference: 8.4 to <9.5 mg/dL in non-PKD patients). PKD patients have lower mortality risk than non-PKD patients in all corrected calcium categories.

Figure 3A shows unadjusted, case-mix and MICS adjusted death HR for time-averaged serum phosphorous levels in PKD patients. Fully adjusted death HRs (95% CI) associated with time-averaged serum phosphorous levels of <3.5, 5.5 to <7.5 and ≥7.5 mg/dL (reference: 3.5 to <5.5 mg/dL) for PKD patients were 2.82 (1.50–5.29), 1.40 (1.12–1.75) and 2.25 (1.57–3.22) (P < 0.001 for the quadratic phosphorous term in case-mix and MICS models), respectively, and a similar pattern was found in non-PKD patients. The association between phosphorous and mortality was not modified by presence of PKD (P > 0.05 for interaction term). Figure 3B shows pooled analyses comparing mortality predictability of serum phosphorous increments in PKD versus non-PKD patients (corrected calcium reference: 3.5 to <5.5 mg/dL in non-
PKD patients). PKD patients had lower mortality risk than non-PKD patients in higher phosphorous categories (≥3.5 mg/dL), but PKD patients had higher mortality risk in the lower phosphorous categories (<3.5 mg/dL).

Figure 4A shows unadjusted, case-mix and MICS adjusted death HRs associated with time-averaged serum alkaline phosphatase levels in PKD patients. Fully adjusted death HRs (95% CI) associated with time-averaged serum alkaline phosphatase levels of <80, 120 to <160 and ≥160 U/L (reference: 80 to <120 U/L) for PKD patients were 0.98 (0.74–1.30), 0.96 (0.68–1.34) and 1.14 (0.80–1.64) (P > 0.05 for the quadratic alkaline phosphatase term in case-mix and MICS models), respectively, and similar pattern was found in non-PKD patients. The association between alkaline phosphatase and mortality was not modified by presence of PKD (P > 0.05 for interaction term). Figure 4B shows pooled analyses comparing mortality predictability of serum alkaline phosphatase increments in PKD versus non-PKD patients (serum alkaline phosphatase reference: 80 to <120 U/L in non-PKD patients). PKD patients had lower mortality risk than non-PKD patients when serum alkaline phosphatase was <120 U/L.

**Discussion**

The analyses of data from a large and nationally representative contemporary cohort of >100 000 non-PKD MHD patients and >1500 PKD MHD patients allow us to make several important observations. Firstly, we confirm the previous findings of an association between higher serum phosphorous level and higher risk for death in MHD patients using a time-averaged analysis. Secondly, the association of different bone–mineral markers and mortality was not modified by presence PKD. Thirdly, despite a similar relationship between bone–mineral markers and mortality in PKD and non-PKD MHD patients, PKD patients had superior survival to non-PKD patients with higher levels of different bone–mineral markers.
In our study, we found a U-shape association between serum PTH and phosphorous level and death risk in PKD and non-PKD patients. However, a recent meta-analysis in CKD patients indicated that only high serum phosphorous level was a strong and independent predictor of mortality [4]. In the Netherlands Cooperative Study on the Adequacy of Dialysis study, in incident HD patients, Noordzij et al. [27] reported that the presence of plasma phosphorous concentrations greater than the Kidney Disease Outcomes Quality Initiative targets increased all-cause mortality risk in HD and peritoneal dialysis patients. This observation was confirmed by others [28, 29]. Here, we reported a similar relationship between serum phosphorous/PTH levels and mortality in MHD patients and showed that this association is not modified by the presence of PKD. Of note, a survival difference between PKD and non-PKD patients still exists in high serum phosphorous and PTH categories. While the high serum phosphorous level is a strong predictor of mortality in both subgroups, the lower death risk of PKD patients compared to non-PKD patients was only present in those with high serum phosphorous level, but not in patients with low phosphorous level. This may indicate that PKD patients are healthier, and high phosphorous level still exists as a risk factor in this subgroup of MHD patients.

Low serum phosphorous/PTH levels were also associated with mortality in both PKD and non-PKD MHD patients. In MHD patients, a serum PTH between 150 and 300 pg/mL is considered a reasonable target zone [30]. A low serum PTH <150 pg/mL, however, may not necessarily be due to the so-called ‘adynamic bone’ but may be another facet of the malnutrition–inflammation complex syndrome (MICS) [31]. An observational study of HD patients by Dukkipati et al. [31] studied the relationship between low PTH and protein–energy malnutrition and inflammation and found that patients with low PTH in the range of 150–200 pg/mL had the greatest survival in this cohort. PTH stimulates lipogenesis through influx of
calcium into the adipocytes [32] and it is thus reasonable to suggest that a low PTH may prevent the accumulation of adipose tissue which may serve as a mechanism for protein–energy wasting in low PTH states. A recent study by Kovesdy et al. [33] showed an association of PTH with obesity in patients with non-dialysis dependent CKD. In vitro PTH secretion is suppressed by interleukin (IL)-6 [34], a strong pro-inflammatory cytokine that is associated with poor outcome in maintenance dialysis patients [35]. IL-1β, another pro-inflammatory cytokine, inhibits PTH secretion in cultured parathyroid tissue slices [36]. This effect may be mediated through the specific IL-1 receptors that upregulate calcium-sensing receptor messenger RNA leading to apparent low bone turnover [36]. Indeed, in the foregoing study, the inhibitory effect of IL-1β could be counteracted by the IL-1 receptor antagonist [36], indicating that the inflammation induced suppression of PTH can potentially be overcome by treatment of malnutrition–inflammation complex in individuals with CKD. Interestingly, we found the worst survival in the lowest levels of PTH and phosphorus, likely markers of inflammation, in PKD patients. Moreover, in these categories, PKD patients had worse survival than non-PKD patients. This might mean that inflammation has bigger impact on survival in PKD than in non-PKD patients. This observation needs further confirmation and more studies.

In the present study, we found U-shape association between serum calcium and mortality in PKD patients, but it was not significant due to the lack of statistical power. A similar U-shaped association was observed previously by our group [23]. Since enhanced calcification of blood vessels, including coronaries, often occurs in CKD patients and is a strong death predictor [37], the hypercalcemia–death associations are often attributed to vascular calcification upon higher calcium load. There have been mixed data about the mortality predictability of low serum calcium in CKD patients. Lowrie and Lew [38] were the first to report increased mortality with calcium <9.0 mg/dL in over 12,000 HD patients. However, Block et al. [28] did not find an increased mortality risk with hypocalcemia in 40,538 HD patients from the Fresenius Dialysis Clinics. Young et al. [39] found that serum calcium concentrations <7.8 mg/dL were associated with lower mortality compared to 9.0–9.5 mg/dL. We also showed this association in non-dialysis-dependent CKD patients, but only when analyzing calcium in time-dependent models, not in time-averaged models [40]. There is a physiological explanation for this short-term mortality caused by acutely lower calcium only, due to arrhythmias [40].

In our study, the association between serum alkaline phosphatase and survival was monotonous, almost strictly upgoing and independent of the level of multivariate adjustment in both PKD and non-PKD patients >120 U/L. PKD did not appear to be an effect modifier in the association between MBD markers and mortality in MHD patients. Despite a similar relationship between bone–mineral markers and mortality in PKD and non-PKD MHD patients, PKD patients had superior survival to non-PKD patients with higher levels of different bone–mineral markers.

Conclusions

A U-shaped association for serum phosphorous, PTH and calcium mortality was observed in MHD independently their PKD status. Additionally, the association between serum alkaline phosphatase and survival was monotonic, almost strictly upgoing and independent of the level of multivariate adjustment in both PKD and non-PKD patients >120 U/L. PKD did not appear to be an effect modifier in the association between MBD markers and mortality in MHD patients. Despite a similar relationship between bone–mineral markers and mortality in PKD and non-PKD MHD patients, PKD patients had superior survival to non-PKD patients with higher levels of different bone–mineral markers.

Acknowledgements. We thank DaVita Clinical Research for providing the clinical data, analysis and review for this research project.

Funding. The study was supported by the research grant K.K.Z. from the American Heart Association grant (0655776Y). Other support for this work was provided by grants from the National Institute of Health (NIH) (DK077341) and DaVita Inc. to K.K.Z. Other funding sources of K.K.Z. include the National Institute of Diabetes, Digestive and Kidney Disease of the NIH (R01 DK078106) and a philanthropic grant from Mr Harold Simmons. M.Z.M. received grants from the National Developmental Agency (KTIA-OTKA-EU ‘7K-P-HUMAN-MB08-A-81231) from the Research and Technological Innovation Fund and was also supported by Hungarian Kidney Foundation.
Conflict of interest statement. Dr K.K.-Z. is the medical director of DaVita Harbor-UCLA/MFI in Long Beach, CA, none of the other authors declare a conflict of interest.

References


Losartan prevents the development of the pro-inflammatory monocytes CD14+CD16+ in haemodialysis patients

Ana Merino1,2,*, Maria Antonia Alvarez-Lara1,2,3,*, Rafael Ramirez1,2, Julia Carracedo1,2, Alejandro Martin-Malo1,2,3 and Pedro Aljama1,2,3

1Instituto Maimónides de Investigación Biomédica de Córdoba (IMIBIC)/Fundación de Investigaciones Biomédicas de Córdoba (FIBICO), Córdoba, Spain; 2Instituto de Salud Carlos III (RETICs Red Renal RD06/0016/0007), Madrid, Spain and 3Nephrology Unit, Reina Sofia University Hospital, Córdoba, Spain

Correspondence and offprint requests to: Ana Merino; E-mail: merino.a76@gmail.com
*Both authors are considered co-authors of this study.

Abstract

Background. The principal cause of mortality in haemodialysis (HD) patients is cardiovascular disease, which is linked to chronic inflammation. Recent studies have demonstrated that angiotensin II receptor AT1 antagonists have anti-inflammatory properties. In this study, we evaluated the effect of losartan on CD14+CD16+ monocytes in HD patients. In addition, we developed an in vitro model to study the mechanisms by which losartan modulates these cells.

Methods. We divided 18 HD patients into two groups, based on anti-hypertensive treatment: 9 patients were treated with losartan (losartan group) and 9 received other anti-hypertensive drugs that did not affect the renin–angiotensin axis (no-losartan group). Losartan was withdrawn in five patients from the losartan group for 2 months. Ten healthy subjects were included as controls. In vitro, we studied the differentiation of monocyes from healthy donors on stimulation with interleukin (IL)-10, IL-4 and granulocyte monocytes colony-stimulating factor with or without losartan in the culture medium.

Results. In patients who were taking losartan, the percentage of monocytes that expressed CD14+CD16+ was lower compared with patients in the no-losartan group. The percentage of CD14+CD16+ was similar in the losartan group and healthy subjects. When losartan was withdrawn from five patients in the losartan group, the percentage of CD14+CD16+ monocytes increased compared with before withdrawal. In vitro, when we added losartan to the culture medium, CD14+CD16+ monocytes failed to differentiate into CD14+CD16+ cells.

Conclusion. Losartan acts as an immunomodulator that prevents the development of CD14+CD16+ pro-inflammatory monocytes in HD patients.

Keywords: CD14+CD16+ monocytes; haemodialysis; losartan

Introduction

The mortality of haemodialysis (HD) patients has remained high despite significant advances in dialysis...